Search for a command to run...
Nephro Care India Ltd. is currently underperforming compared to its peers in terms of financial metrics, with no reported growth or profitability metrics. Among its peers, companies like Max Healthcare and Apollo Hospitals show strong profitability and growth, while firms like Fortis Healthcare appear overvalued. Aster DM Healthcare emerges as a deep value pick despite its financial weaknesses, making it a potential target for investors focused on valuation.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
NEPHROCARE | - | - | 0.00 | - | - |
MAXHEALTH | ₹1,179.65 | ₹1,14,679.30Cr | 163.58 | 16.26% | 0.14 |
APOLLOHOSP | ₹7,676.95 | ₹1,10,383.03Cr | 85.15 | 21.19% | 0.67 |
FORTIS | ₹924.85 | ₹69,822.29Cr | 1094.63 | 12.01% | 0.11 |
MEDANTA | ₹1,395.25 | ₹37,474.60Cr | 81.26 | 20.50% | 0.10 |
NH | ₹1,784.05 | ₹36,459.02Cr | 84.56 | 21.62% | 0.61 |
ASTERDM | ₹605.10 | ₹30,225.53Cr | 5.05 | 11.46% | 0.19 |